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Background and Aim: The association between the rs9939609 polymorphism of fat
mass and obesity-associated gene (FTO) and risk of colorectal cancer is controversial.
This study aims to evaluate the relationship between FTO rs9939609 polymorphism and
colorectal cancer (CRC) in Iranian people.
Methods: A case-control study was conducted on 125 patients with CRC and 250 healthy
subjects in Tehran, Iran. Demographic data and blood samples were collected from all
participants. Genotyping of rs9939609 polymorphism was performed by the tetra-primer
amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) method.
Results: The occurrence of AA genotype of FTO rs9939609 polymorphism in the
colorectal cancer patients was significantly higher compared to that of healthy subjects
(16.4 vs. 2.9%, respectively, P=0.02). The association between the frequency of risk allele
of the FTO polymorphism and CRC (B=1.67, P=0.042) remained significant after
adjustment for age. Further adjustment for gender (model 2) and marital status (model 3)
did not change this result (B=1.67, P= 0.042 and B=1.67, P=0.043, respectively). The
results remained significant after additional adjustment for ethnicity (B=1.57, P= 0.047).
Conclusion: We found a positive association between the A allele of the rs9939609
polymorphism and CRC. Future studies are required to identify the underlying
mechanisms.
Keywords: colorectal cancer, fat-mass- and obesity-associated (FTO) gene, polymorphism, genotype, colon cancerSeptember 2021 | Volume 11 | Article 7325151
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Colorectal cancer (CRC), also known as bowel cancer, colon
cancer, rectal cancer, is characterized by the abnormal growth of
tissue in the large intestine leading to cancer (1). With 1–2
million new cases and 700,000 deaths every year, CRC is one of
the most common cancers worldwide (2). CRC is among the top
three cancers most diagnosed, with an incidence rate of 11% of
all cancers. CRC is more prevalent among men than women (3).
While the incidence of CRC is high in developed nations, there
are rapid increases in cases in developed countries, including
Iran. Based on a screening program completed in 2018, 33
Iranians per 100,000 have CRC (4). There has been a
year-to-year increase in the overall risk of developing this
cancer among the Iranians (5).
The pathophysiology leading to CRC development includes a
complex interaction of genotype and environment (lifestyle)
factors. The lifestyle factors include excessive indulgence of
highly processed and Westernized dietary habits; consumption
of highly refined sugars, animal fats; low consumption of fruits
and vegetables; consumption of tobacco and alcohol; and low
physical activities (6–9). Several recent studies identified obesity
as an independent risk factor for CRC across all age groups,
further suggesting the role of lifestyle factors in CRC (10). The
body mass index (BMI) greater than 30 kg/m2 is an independent
risk factor of CRC. Genetic factors are estimated to account for
40–70% of obesity causes, and therefore, identifying the genetic
loci linked to the development of obesity and CRC has distinct
advantages. Genetic determinants/markers are independent of
the effect of the environmental/lifestyle factors; once the risk
allele is identified, the marker can be measured precisely. Genetic
markers are not affected by disease stage and may represent
lifelong risk factors of the disease (11).
Several GWAS studies suggested that CRC has a strong
genetic basis. To date, more than 50 unique genetic loci, many
with a known biochemical basis, are mapped to have an
association with the incidence of CRC across different ethnicity
(12). Fat-mass- and obesity-associated (FTO) gene codes a
polypeptide with 505 amino acids and is a common genetic
determinant for obesity and cancer (13). Human FTO protein is
expressed in the brain, skeletal muscle, and adipose tissue (8).
The expression of FTO within the arcuate nucleus of the
hypothalamus is essential for regulating appetite and energy
metabolism (14). An excessive expression of FTO increases
food intake, thereby leading to a positive energy balance linked
to obesity. Hence, FTO expression is suspected to be a risk factor
for several cancers as it could result in poorer prognosis and
potentially affect therapeutic efficacy (10). Several studies have
reported a strong association of the FTO polymorphisms with
the risk of developing obesity (9). Recent epidemiological studies
also indicated that FTO variants are involved in obesity-associated
colon cancer (15). For instance, the FTO polymorphisms
rs17817449 and rs8050136 were positively associated with
obesity-associated colorectal cancer in African-Americans
(11). The FTO rs9939609 variant was identified as
an etiological genetic factor for obesity in Italians (16).Frontiers in Oncology | www.frontiersin.org 2However, no direct association of this variant with the
CRC risk in the Italians was revealed by another study (7). A
meta-analysis of 12 studies including 5,000 cases and 9,853
controls found that the rs9939609 variant was significantly
associated with the increased risk of obesity in children and
adolescents (17).
Based on the fact that the FTO rs9939609 variants have
shown an association with obesity in various ethnicity and
obesity is a risk factor for CRC aetiology, the objective of this
study was to investigate the genetic association of FTO
rs9939609 variants with the risk of developing CRC in Iranians.METHODS
Study Population
This study was a hospital-based case-control study conducted
between January 2021 and June 2021 on a total 375 participants
including 125 patients with pathologically confirmed stage 4
CRC as the case group and 250 healthy people as the control
group. The CRC patients were histologically diagnosed as having
primary colorectal cancer and underwent surgical operation at
Firoozgar Hospital, Tehran, Iran in 2020–2021. Due to the fact
that all the patients were collected from one hospital and all of
them were on the same stage of the disease and underwent
surgery, they were treated with the same drugs. The controls
were randomly selected from a prospective cohort study among a
general Iranian population. The inclusion criteria of the case
group included willingness to participate in this study, confirmed
histopathologic of CRC in individuals, maximum 6 months
elapsed since diagnosis, and age range of 35 to 70 years.
Inclusion criteria of the healthy control group included
willingness to participate in this study, having no malignancy,
and age range of 35 to 70 years. Socio-demographic variables
including age, gender, marital status, and ethnicity were collected
through a face-to-face interview. This study was approved by the
ethics committee of Shahid Beheshti University of Medical
Sciences, Tehran, Iran (code: IR.SBMU.CRC.REC.1398.028).
All participants were explained about the details of the present
study, and a written consent was obtained prior to the
data collection.
Genotyping
At the beginning of the study, 5 ml of venous blood from all
individuals was collected into EDTA tubes (EDTA K3, Shandong
Weigao Group Medical Polymer Co., Ltd, China). The salting
out method was utilized to extract deoxyribonucleic acid (DNA)
from the 200 ml of whole blood samples previously stored at
−70°C. The polymerase chain reaction (PCR) was performed to
amplify the extracted DNA using a PCR amplification
instrument (GeneQ; Hangzhou Bioer Technology Co., Ltd.,
Hangzhou, China) and master mix DNA polymerase (cat. No
A180301; Ampliqon, Denmark). The tetra-primer amplification
refractory mutation system-polymerase chain reaction
(T-ARMS-PCR) was then utilized to determine the genotype ofSeptember 2021 | Volume 11 | Article 732515
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primers are presented in (Table 1).
Statistical Analysis
Hardy-Weinberg equilibrium was used for evaluation of
genotype distribution. General characteristics of the patients
and healthy participants and the frequency of the FTO
rs9939609 polymorphism in the case and control groups
were compared by chi-square (for qualitative variables) and
independent t-test (for quantitative variables) methods.
Binary logistic regression analysis was performed, and
regression models were fitted to investigate the association
between CRC and the risk allele based on the dominant
genetic model (TT vs. AT+AA) after adjusting for age
(model 1); age and gender (model 2); age, gender, and
marital status (model 3); age, gender, marital status, and
ethnicity (model 4). The confounders were selected based
on previous investigations (11). The statistical analyses were
performed using SPSS software version 20 (SPSS Inc., Chicago,
USA), and in all analyses, P-value <0.05 was considered as
statistically significant.RESULTS
The general characteristics of the patients and healthy
participants included in this study are presented in Table 2.
The mean (± SD) age in the case and control groups was 53.2 (±
1.34) and 41.63 (± 1.89) years, respectively (P <0.05). Between
the case and control groups, significant differences exist for the
marital status (P<0.01) of the participants, with the case groups
having a lower number (6.4%) of single participants compared to
the control group (23.5%). There was no significant difference
between the two groups in terms of gender, weight, height, and
BMI. The participants represent six different ethnicity
subclusters within Iranians, with no significant difference
between the case versus control groups for any of the
subclusters. The genotype frequencies in both control and
pathological subjects did not deviate from the Hardy–
Weinberg equilibrium (P=0.06 and 0.87, respectively).
Genotyping of the FTO rs9939609 polymorphism revealed a
significant difference (P<0.05) between the case versus the
control groups. The AA genotype is over-represented in the
cases (16.4%) than the controls (10%) (Figure 1).Frontiers in Oncology | www.frontiersin.org 3The association between FTO rs9939609 polymorphism and
CRC was investigated by logistic regression, and the results are
presented in (Table 3). The association between the risk allele
(A) and the incidence of CRC (B=1.67, P<0.05) remained
significant after adjustment for age. Further adjustment for
gender (model 2) and marital status (model 3) did not change
this result (B=1.67, P= 0.042 and B=1.67, P=0.043, respectively).
The effect remained significant even after additional adjustment
for the ethnicity (B=1.57, P= 0.047) of the participants.DISCUSSION
The present study investigated the genetic association of FTO
rs9939609 variant with the risk of developing colorectal cancer
in 375 Iranians (125 patients and 250 healthy) volunteers. The
genotyping revealed that the risk allele (A) is over-represented
in the patients’ group. There is a significant positive
association of the A allele with the risk of developing CRC in
Iranians. The association of FTO rs9939609 variants with the
CRC in Iranian evident in this study further suggested the
shared role of energy metabolism and obesity pathways in
colorectal cancer.
The present case‐control study identified the genetic
association of FTO rs9939609 variant with colorectal cancer in
Iranians with the A allele over-represented in the patient group.
Fat-mass- and obesity-associated (FTO) gene codes a
polypeptide (13) and is predominantly expressed in the brain,
skeletal muscle, and adipose tissue (8). The expression of FTO
within the arcuate nucleus of the hypothalamus is necessary forTABLE 1 | The features of primers used in this study.
Gene Primer sequence Product size Annealing
temp. °C












59.5TABLE 2 | Characteristics of study population.
Characteristics Control (n = 250) Case (n = 125) P-value
Age (y)* 41.63 ± 1.89 53.2 ± 1.34 <0.001†
Gender‡
Male 32 (47.1%) 61 (55.5%) 0.276¶
Female 36 (52.9%) 49 (44.5%)
Weight (kg) 70.2 ± 8.6 69.7 ± 10.9 0.74
Height (cm) 159.27 ± 8.4 156.19 ± 5.6 0.07
BMI (kg/m2) 27.63 ± 3.1 28.58 ± 4.1 0.08
Marital Status‡
Single 58 (23.5%) 8 (6.4%) 0.003¶
Married 187 (75.0%) 112 (89.1%)
Divorced 5 (1.5%) 5 (4.5%)
Ethnicity‡
Persian 183 (73.4%) 76 (61.0%) 0.528¶
Turkish 43 (17.2%) 33 (25.6%)
Lor 20 (7.8%) 9 (7.3%)
Kurdish 4 (1.6%) 5 (3.7%)
Arab 0 1 (1.2%)
Other 0 1 (1.2%)
Genotype (rs9939609)‡
0 (TT) 85 (34%) 45 (36.4%) 0.020¶
1 (AT) 140 (56%) 59 (47.3%)
2 (AA) 25 (10%) 21 (16.4%)September 2021 | Volume 11 | Article*Values are means ± SD.
†P-values obtained using t test.
‡Number of participants having the characteristic (%).
¶P-values obtained using Chi-square test.732515
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expression of FTO increases food intake, leading to a positive
energy balance and obesity. However, the FTO rs9939609 variant
being an SNP present in the first intronic region of the transcript,
the underlying molecular mechanism of this SNP is
not apparent.
The FTO mediates one common pathway of obesity and
cancer via 6-methyl adenosine (m6A)-dependent demethylase
activity (18). The m6A-dependent demethylase activity enables
regulating the abundance and stability of mRNA of several genes,
including the genes involved in satiety and hunger (ghrelin and
leptin), and mTOR, a key component of regulating mRNA
translation and cell growth, thus regulating the occurrence and
progression of obesity and cancer (15). The FTO protein also acts
as a nutrient sensor that can play a role in cell growth and
proliferation. Experimental knockdown of the FTO gene resulted
in disruption of cellular energy balance (15). Numerous
experiments demonstrated a vital role of obesity and excessive
food intake in the complex metabolic regulation of CRC
tumorigenesis (ref). Expression of adipokines, hunger and
satiety hormones, dysbiosis of the intestinal microbiota, and
impaired bile acid homeostasis are some of the shared
mechanisms underlying tumorigenesis of CRC and metabolic
syndrome (19). FTO gene expression increased after intake of
macronutrients such as carbohydrates and proteins that play a
key role in the tumour formation process (19).
Obesity is associated with insulin resistance and
hyperinsulinemia, resulting in increased production of growth
factors necessary to support tumorigenesis, leading to
carcinogenesis. Oxidative stress and inflammatory processes are
other complications of obesity that are also involved in
carcinogenesis (12, 19). Moreover, there is evidence that the A
allele of the FTO rs9939609 is significantly associated with higher
serum leptin concentrations (20), even independently of adiposity
and BMI (21). Meanwhile, recent studies have reported that leptin
may be involved in colorectal cancer development and progression
(22, 23). These evidence indicates that leptin could be a possible
intermediary contributing to the association between the FTO
rs9939609 polymorphism and colorectal cancer. Therefore, it is
reasonable to expect that if FTO variants have a genetic association
with obesity, they are also likely to have a close genetic association
with CRC.
One possible mechanisms of the association between FTO
with CRC is the role of obesity as a chronic inflammatory
stimulus in carcinogenesis. C-reactive protein (CRP) may
facilitate monocyte adhesion and macrophage infiltration in
the pathological tissue and can boost angiogenesis, a key
hallmark of CRC (24). A recent study reported that
pharmacological inhibition of FTO dramatically attenuated cell
self-renewal and reprogrammed immune response by
suppressing expression of immune checkpoint genes. FTO
inhibition sensitizes leukemia cells to T cell cytotoxicity and
overcomes hypomethylating agent-induced immune evasion,
indicating the broad potential of targeting FTO for cancer
therapy (25).
Nevertheless, there are reports of associations of FTO
polymorphism with the susceptibility of developing various cancerFIGURE 1 | Number of risk alleles of FTO rs9939609 gene polymorphism in
the case and control groups.TABLE 3 | Beta estimates and confidence intervals for the association between
FTO rs9939609 polymorphism and CRC.
Model Components Chi-square df B P-value
Model 1 21.46 3 0.000
Genotype (TT) 0.111
Genotype (TA) −1.325 0.111
Genotype (AA) −1.666 0.042
Age 0.042 0.000
Model 2 22.89 5 0.000
Genotype (TT) 0.118
Genotype (TA) −1.380 0.099
Genotype (AA) −1.672 0.042
Gender −0.438 0.231
Age 0.041 0.001
Model 3 25.26 10 0.005
Genotype (TT) 0.124
Genotype (TA) −1.424 0.090
Genotype (AA) −1.676 0.043
Gender −0.542 0.154
Marital (Unmarried) 0.327
Marital (Married) −1.190 0.422
Marital (Unknown) −0.213 0.869
Age 0.029 0.039
Model 4 29.00 11 0.002
Genotype (TT) 0.170
Genotype (TA) −1.269 0.143
Genotype (AA) −1.570 0.067
Gender (Male) −0.506 0.191
Ethnicity (Fars) 0.852
Ethnicity (Turk) −21.295 1.000
Ethnicity (Lor) −20.911 1.000
Ethnicity (Kurd) −21.117 1.000
Ethnicity (Arab) −19.685 1.000
Ethnicity (Others) −2.263 1.000
Marital (Unmarried) 0.313
Marital (Married) −1.277 0.396
Marital (Unknown) −0.265 0.840
Age 0.030 0.038September 2021 | Volume 11 | Article 732515
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mass index and weight might be confounding factors in the
association between FTO polymorphism and cancer risk. A cross-
sectional study also reported that A-allele of rs9939609
polymorphism was associated with higher probability of
developing inflammatory bowel disease (IBD) that was
independent from the BMI status of the patients (28). At the
same time, those IBD patients were reported to have the high risk
for developing CRC (29). Hence, it may be plausible to expect that
the association between FTO polymorphism and colorectal cancer
may be independent of its association with obesity-related traits.
The rs9939609 variant is one of the extensively studied SNPs
of the FTO gene. This SNP was found to have genetic association
with obesity-related traits. Frayling et al. reported that 16%
adults carrying AA genotype weigh 3 kg more and had a 1.67-
fold greater odds of developing obesity compared the genotype
without A allele. While the FTO can contribute to the
development of cancer through affecting several biochemical
pathways (30), genetic association between rs9939609
polymorphism and the risk of developing cancers was reported
(31). However, to date, only a few studies investigated the
association of rs9939609 variant with the risk of developing
CRC (11, 32). In contrast to those two studies that have not
found any association of this variant with CRC in the Caucasians
and mixed ethnicity, our study identified a positive association
between the A allele and increased susceptibility to CRC in the
Iranian patients.
A significant association between rs9939609 variants and the
risk of developing other types of cancer, such as kidney cancer,
pancreatic cancer, breast cancer, and endometrial cancer, was
reported (31, 33–35). In a case-control analysis with 3,601 non-
Hispanic white women with endometrial carcinoma and 5,275
controls, the A allele of rs9939609 was found to be associated
with an increased risk of endometrial cancer (36). On the other
hand, a few studies also reported associations of the A allele of
rs993609 variants with a reduced risk of cancers such as the risk
of lung cancer (35), while several other studies found no relation
between this variant and cancer risk (11, 32, 37).
However, this study has some limitations. First, the sample
size was relatively small and the mean age of the control group
was significantly different from the case group. However, the
effect of age on the results was adjusted in regression models.
Second, the association found between CRC and an FTO
genotype in this study with retrospective design (not
experimental) does not necessarily mean one factor directly
caused the other. Third, the cases in this study were defined by
whether they did or did not have the condition, and the results
cannot confirm the association of FTO gene with different types
of the disease. Fourth, some confounding variables such as diet
and physical activity were not considered in this study. The
association of A allele with the Iranian CRC patients reported in
this study warrants further validation through genotyping largerFrontiers in Oncology | www.frontiersin.org 5sample size and study designs, taking into consideration the age
and ethnicity of the populations (30).CONCLUSION
In conclusion, this study identified a positive association between
the A allele of rs9939609 polymorphism and increased
susceptibility to CRC in the Iranian subjects. Further studies
addressing the functional impact of this FTO polymorphism in
the human colon and rectum and understanding of the
underlying mechanism of the association of FTO gene with
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